Want to see NRXS full AI Analyst Report?
NRXS Stock Chart & Stats
$6.80
-$0.06(-0.88%)
At close: 4:00 PM EDT
$6.80
-$0.06(-0.88%)
Day’s Range― - ―
52-Week Range$2.21 - $9.33
Previous Close$6.74
Volume110.77K
Average Volume (3M)55.04K
Market Cap
$77.23M
Enterprise Value$80.56
Total Cash (Recent Filing)$8.32M
Total Debt (Recent Filing)$279.39K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 17, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding12,557,765
10 Day Avg. Volume34,967
30 Day Avg. Volume55,039
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)12.13
Price to Sales (P/S)11.55
P/FCF Ratio-6.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$9.75M
Bulls Say, Bears Say
Bulls Say
Revenue And Adoption GrowthStrong revenue growth, higher unit deliveries, and more ordering accounts indicate expanding provider adoption. Rising revenue per account suggests utilization is deepening, supporting a scalable commercialization model over the next several quarters.
High And Improving Gross MarginsGross margins above 85% and continued expansion indicate attractive device economics and improving reimbursement mix. As full-reimbursement payers replace discounted assistance, incremental revenue should retain substantial contribution potential.
Payer And VA Channel ExpansionThe VA contract creates a structurally larger distribution channel, while commercial payer progress can broaden eligible patient access. Additional coverage and dedicated sales hiring could materially expand the addressable market if execution continues.
Bears Say
Persistent Losses And Cash BurnThe company remains materially loss-making and cash-consuming despite improving trends. Continued investment and expected higher second-half burn increase reliance on external funding, making eventual breakeven essential for financial durability.
Incomplete Payer And Medicaid CoverageCoverage gaps directly limit patient access, provider activation, and reimbursement visibility. Delayed Medicaid implementation could slow account launches and prevent the company from converting its clinical opportunity into broad, repeatable demand.
Clinic Capacity Limits UtilizationProvider capacity, workflow limitations, and insufficient clinic time can constrain treatment volume even where reimbursement exists. These bottlenecks may delay revenue conversion and require additional customer support and operational investment.
NeurAxis, Inc. News
NRXS FAQ
What was NeurAxis, Inc.’s price range in the past 12 months?
NeurAxis, Inc. lowest stock price was $2.21 and its highest was $9.33 in the past 12 months.
What is NeurAxis, Inc.’s market cap?
NeurAxis, Inc.’s market cap is $77.23M.
When is NeurAxis, Inc.’s upcoming earnings report date?
NeurAxis, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 85 days.
How were NeurAxis, Inc.’s earnings last quarter?
NeurAxis, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.13.
Is NeurAxis, Inc. overvalued?
According to Wall Street analysts NeurAxis, Inc.’s price is currently Overvalued.
Does NeurAxis, Inc. pay dividends?
NeurAxis, Inc. does not currently pay dividends.
What is NeurAxis, Inc.’s EPS estimate?
NeurAxis, Inc.’s EPS estimate is -0.16.
How many shares outstanding does NeurAxis, Inc. have?
NeurAxis, Inc. has 12,557,765 shares outstanding.
What happened to NeurAxis, Inc.’s price movement after its last earnings report?
NeurAxis, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -7.569%.
Which hedge fund is a major shareholder of NeurAxis, Inc.?
Currently, no hedge funds are holding shares in NRXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeurAxis, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
NRXS Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.03%
Trailing 12-Months
Company Description
NeurAxis, Inc.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
NRXS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and measurable operational improvements: double-digit, high-percentage revenue growth (116% YoY Q2), rising ASP and unit deliveries, gross margin expansion, improved KPIs, tangible payer engagement and concrete commercialization hires and VA opportunity. At the same time, meaningful challenges remain: limited payer coverage and state Medicaid implementation gaps limit penetration, operational capacity constraints create patient wait times, and the company is still operating at a loss with a going-concern note until cash flow breakeven is achieved. Management presented a clear plan (targeted market execution, additional payer outreach, new hires and VA expansion) and expects short-term increased OpEx to accelerate revenue. Overall the positives — strong growth, improving margins and concrete payer/VA progress — appear to outweigh the risks and required investments, though execution on payer wins and scaling clinic capacity remain critical.View all NRXS earnings summariesTechnical Analysis
Ownership Overview
12.17% Insiders
2.39% Mutual Funds
12.71% Other Institutional Investors
69.72% Public Companies and
Individual Investors